Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy.

IF 2.7 3区医学 Q3 ONCOLOGY Strahlentherapie und Onkologie Pub Date : 2024-08-01 Epub Date: 2024-02-28 DOI:10.1007/s00066-024-02208-8

Susana Castro-Larefors, Maria Magdalena Marti-Laosa, Veronica Lopez-Honrubia, Irene Rey-Lopez, Beatriz Ruiz-Herrero, Yasmina Murria-Perez, Ignacio Andres, Isabel Elvira Jimenez-Garcia, Roberto Berenguer, Manuel Aguayo-Martos, Ricardo Sánchez-Prieto, Angeles Rovirosa, Esther Jimenez-Jimenez, Meritxell Arenas, Sebastià Sabater

{"title":"Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy.","authors":"Susana Castro-Larefors, Maria Magdalena Marti-Laosa, Veronica Lopez-Honrubia, Irene Rey-Lopez, Beatriz Ruiz-Herrero, Yasmina Murria-Perez, Ignacio Andres, Isabel Elvira Jimenez-Garcia, Roberto Berenguer, Manuel Aguayo-Martos, Ricardo Sánchez-Prieto, Angeles Rovirosa, Esther Jimenez-Jimenez, Meritxell Arenas, Sebastià Sabater","doi":"10.1007/s00066-024-02208-8","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the impact of sustained hypogonadism after androgen deprivation therapy (ADT) associated with radiotherapy in prostate cancer (PCa) patients with biochemical relapse-free survival (bRFS).Methods: A retrospective cohort analysis of 213 consecutive PCa patients referred for radiotherapy plus ADT was carried out. Follow-up times including time to testosterone recovery (TTR) and bRFS were calculated from the end of ADT. Univariate and multivariate Cox regression analyses predicting bRFS were used. The optimal cutoffs for TTR and duration of ADT were determined using the maximally selected rank statistics (MSRS).Results: After a median follow-up of 104 months, 18 patients relapsed among those who had recovered testosterone levels and 9 among those who did not. Median ADT duration was 36 months. The optimal cutoff for TTR was determined using MSRS. TTR >48 months was significantly associated with better bRFS (logrank, p < 0.0027). Five-year bRFS was 100% for >48 months vs. 85% for <48 months. TTR was the only significant variable for bRFS in multivariate Cox analysis.Conclusion: Our data show an association between longer TTR and bRFS values among PCa patients treated with ADT.","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"691-697"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-024-02208-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the impact of sustained hypogonadism after androgen deprivation therapy (ADT) associated with radiotherapy in prostate cancer (PCa) patients with biochemical relapse-free survival (bRFS).

Methods: A retrospective cohort analysis of 213 consecutive PCa patients referred for radiotherapy plus ADT was carried out. Follow-up times including time to testosterone recovery (TTR) and bRFS were calculated from the end of ADT. Univariate and multivariate Cox regression analyses predicting bRFS were used. The optimal cutoffs for TTR and duration of ADT were determined using the maximally selected rank statistics (MSRS).

Results: After a median follow-up of 104 months, 18 patients relapsed among those who had recovered testosterone levels and 9 among those who did not. Median ADT duration was 36 months. The optimal cutoff for TTR was determined using MSRS. TTR >48 months was significantly associated with better bRFS (logrank, p < 0.0027). Five-year bRFS was 100% for >48 months vs. 85% for <48 months. TTR was the only significant variable for bRFS in multivariate Cox analysis.

Conclusion: Our data show an association between longer TTR and bRFS values among PCa patients treated with ADT.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

睾酮恢复时间越长，对雄激素剥夺和放疗后的前列腺癌治疗效果越有利。

目的：评估前列腺癌（PCa）患者在接受与放疗相关的雄激素剥夺疗法（ADT）后持续性性腺功能减退对无生化复发生存期（bRFS）的影响：对213名连续接受放疗加ADT治疗的PCa患者进行了回顾性队列分析。从 ADT 结束开始计算随访时间，包括睾酮恢复时间（TTR）和 bRFS。采用单变量和多变量 Cox 回归分析预测 bRFS。使用最大选择秩统计（MSRS）确定了TTR和ADT持续时间的最佳临界值：中位随访104个月后，睾酮水平恢复的患者中有18人复发，未恢复的患者中有9人复发。中位 ADT 持续时间为 36 个月。使用 MSRS 确定了 TTR 的最佳临界值。TTR >48 个月与较好的 bRFS 显著相关（对数秩，p 48 个月 vs. 85% 结论：TTR >48 个月与较好的 bRFS 显著相关：我们的数据显示，在接受 ADT 治疗的 PCa 患者中，较长的 TTR 值与 bRFS 值之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.